Integra LifeSciences Holdings CorporationIARTNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -0.41% | +11.49% | +3.74% | -0.61% | +5.57% |
| Gross Profit Growth | -8.29% | +9.97% | -6.00% | -7.34% | +12.92% |
| EBITDA Growth | -43.80% | +7.50% | -33.35% | -1273.42% | +54.59% |
| Operating Income Growth | -130.65% | -1.17% | -490.94% | +0.00% | +0.00% |
| Net Income Growth | -154.85% | -2.01% | +0.00% | +0.00% | +0.00% |
| EPS Growth | -158.33% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | -158.33% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | -4.07% | -1.68% | -1.64% | -1.22% | +0.40% |
| Weighted Average Shares Diluted Growth | -4.21% | -1.68% | -1.64% | -1.22% | +0.40% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -16.01% | -13.63% | -171.45% | -77.92% | +81.93% |
| Free Cash Flow Growth | -152.30% | -67.30% | -13906.53% | -204.98% | +0.00% |
| Receivables Growth | -6.89% | +5.03% | +4.71% | +2.42% | +5.58% |
| Inventory Growth | +19.30% | +10.13% | +10.41% | +10.28% | +11.94% |
| Asset Growth | +8.73% | +6.75% | -0.62% | -9.98% | -10.31% |
| Book Value per Share Growth | +0.44% | -1.02% | -3.03% | -31.46% | -32.08% |
| Debt Growth | +17.76% | +18.01% | -1.15% | +0.21% | +0.83% |
| R&D Expense Growth | +3.15% | +28.52% | -8.30% | -9.31% | -18.15% |
| SG&A Expenses Growth | +9.41% | +9.44% | +9.47% | -7.97% | -4.60% |